Matches in Nanopublications for { ?s ?p "DDI between Atazanavir and Zopiclone - Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if atazanavir is initiated, discontinued or dose changed. [drugbank_resource:DB01072_DB01198]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB01072_DB01198 label "DDI between Atazanavir and Zopiclone - Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if atazanavir is initiated, discontinued or dose changed. [drugbank_resource:DB01072_DB01198]" assertion.